News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Adjuvant Everolimus in Patients with Completely Resected, High-risk Renal Cell Carcinoma – European Urology
Photo of Primo Lara taken from ucdavis.edu
Sep 29, 2024, 09:49

Adjuvant Everolimus in Patients with Completely Resected, High-risk Renal Cell Carcinoma – European Urology

European Urology shared on X:

“Platinum Priority – Kidney Cancer: Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial by Primo Lara et al.

Read the full article here.

Come back tomorrow for the Editorial!

Adjuvant Everolimus

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

Authors: Primo N. Lara, Catherine Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell Meng, Ajjai Shivaram Alva, Sumanta K. Pal, Igor Puzanov,  Joseph I. Clark, Toni K. Choueiri, Neeraj Agarwal, Robert Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Seth Lerner, Ian M. Thompson, Christopher W. Ryan

Adjuvant Everolimus

Source: European Oncology/X

 

Ajjai Shivaram Alva Brian M. Shuch cancer Catherine Tangen Christopher W Ryan Elisabeth I. Heath Ian M. Thompson Igor Puzanov Joseph I. Clark kidney cancer Mark N. Stein Maxwell Meng Melissa Plets Naomi B Haas Neeraj Agarwal OncoDaily Oncology Primo N Lara renal cell carcinoma Robert Uzzo Seth Lerner Shuchi Gulati Sumanta K. Pal Timothy W. Synold Toni K. Choueiri Ulka N. Vaishampayan
Special Coverage
Blog
Mar 22, 2025, 16:27
Anal Cancer Awareness Day
Blog
Mar 22, 2025, 15:19
Applications are open for the 2025 Patient Education Ambassadors Program - Jasmine Kamboj
Blog
Mar 22, 2025, 14:55
Roupen Odabashian: My ViVE experience
Blog
Mar 22, 2025, 14:41
Lydia Asana: 2025 ReGROW - Funding for LMIC Researchers
Blog
Mar 22, 2025, 14:28
The third NIHR Impact Prizes investigator winner is the STAMPEDE trial - NIHR
Blog
Mar 22, 2025, 13:46
NFCR kicked off the Pediatric Cancer Match Campaign
Blog
Mar 22, 2025, 13:29
Penilla Gunther: FOKUS Patient Future Days - something to remember
Blog
Mar 22, 2025, 13:16
Liz Connolly: Systemic treatments in advanced angiosarcoma
Drugs
Mar 22, 2025, 13:05
Zeynep Irem Ozay: Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US
Blog
Mar 22, 2025, 12:47
Naveen Pemmaraju: Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs
Blog
Mar 22, 2025, 12:27
The first 'PSCC Thursday' in Villejuif - Paris Saclay Cancer Cluster (PSCC)
Blog
Mar 22, 2025, 12:06
Thor Halfdanarson: CUP is increasingly precision oncology